Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale
Leukemia
.
2019 Feb;33(2):565-566.
doi: 10.1038/s41375-018-0359-7.
Epub 2019 Jan 11.
Authors
Sarah A Holstein
1
,
Vera J Suman
2
,
Philip L McCarthy
3
Affiliations
1
Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
[email protected]
.
2
Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
3
Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
PMID:
30635635
DOI:
10.1038/s41375-018-0359-7
No abstract available
Publication types
Comment
MeSH terms
Autografts
Humans
Lenalidomide
Multiple Myeloma*
Thalidomide
Transplantation, Autologous
Substances
Thalidomide
Lenalidomide